Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Warning Letters Mount As FDA Completes Initial Inspections Of Under-The-Radar Facilities

Executive Summary

Later this year, FDA expects to complete initial inspections of every facility that manufactures drugs for the US market. As the agency visits under-the-radar facilities recently targeted as part of an effort to leave no site uninspected, it is finding that they are more likely to have serious drug GMP issues.

You may also be interested in...



Drug Quality Focus On Asia, OTCs Supported By US FDA's Second GMP Data Report

OTCs and other "no-application" products remain a drag on overall quality, agency finds in annual quality report, while India and China continue to pose challenges.

Drug Quality Focus On Asia, OTCs Supported By New US FDA Data

OTCs and other "no-application" products remain a drag on overall quality, agency finds in annual quality report, while India and China continue to pose challenges.

New Jersey OTC Firm Lacked GMP Basics, FDA Warning Letter Says

US FDA warns that Health Pharma USA was shipping product before its quality unit could review and test it.

Related Content

Topics

UsernamePublicRestriction

Register

PS123275

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel